Korean Chinese Japanese
  • Economy
  • Politics
  • Society
  • Securities
  • Real estate
  • Culture
  • Entertainment
  • Sports
  • Opinion
Korean Chinese Japanese
Economy Corporation Pharma & Bio
Society Politics IT·Science
Securities Real Estate Global
Opinion Entertainment Sports Culture
Video Auto in Golf in
PHARM EDAILY Market in TheBeLT
Pharma & Bio
Technology

[Report] “AI Eyes” Appear on the Ketotop Production Line… The Evolving HANDOK Inc. Voice Factory

Seo Eui-yeon, Head of the Production Support Office at HANDOK Inc., explains the solid dosage form production process on a screen displaying equipment linked to digital data at the HANDOK Eumseong Pro…
  • 2026-09-03 08:02:02
  • Minji Son
Lifestyle

HLB INC.’s Second Promising Drug, ‘Lirapugratinib’: The Fate of Its U.S. Approval [Monthly Insight]

The most notable issue in the pharmaceutical and biotech industry this September is HLB INC.(028300)’s second attempt to gain approval in the U.S. HLB is awaiting approval from the U.S. Food and Drug …
  • 2026-09-03 07:01:03
  • Kim Jinsoo
Technology

CHONGKUNDANG Takes the Lead in Domestic Development of New U.S. Retinal Drug… Expanding into Rare Eye Diseases

(Graphic: ChatGPT) CHONGKUNDANG(185750)is embarking on the development of a new drug for rare eye diseases by acquiring “KIO-301,” a new drug candidate for retinal diseases from U.S.-based Kiora P…
  • 2026-09-03 07:01:02
  • Minji Son
Technology

Kim Ju-hee, CEO of Inventage Lab Inc.: “SC Formulation Platform Signs MTAs with Multiple Domestic Companies... Begins Validation of Actual Antibodies”

Inventage Lab Inc.(389470)The company has begun technical validation of its next-generation subcutaneous (SC) formulation modification platform, “IVL-BioFluidic™.” It has signed Material Transfer Agre…
  • 2026-09-02 11:47:01
  • NA EUN-KYUNG
Business·Industry

Outcomes of Some M&A Deals Remain Uncertain… Future Investment Performance to Be Watched Closely [PharmaResearch Deep Seek ③]

PharmaResearch(214450)is accelerating its mergers and acquisitions (M&A) and overseas business expansion, leveraging its strong earnings growth. Although some subsidiaries continue to post losses and …
  • 2026-09-02 09:31:02
  • KIM SAE-MI
Technology

“My Cat Will Live to Be 30?”… The Truth Behind the Buzz Surrounding a New Japanese Drug

(Graphic: ChatGPT) A treatment for chronic kidney disease (CKD) that is said to extend a cat’s lifespan by up to 30 years is generating buzz, particularly on social media. This is due to “FeliAIM,…
  • 2026-09-02 09:06:02
  • Minji Son
Technology

Cellid Surges on COVID Fears; VUNO Plunges on Rights Offering [K-Bio Pulse]

South Korean biotech and healthcare stocks showed sharply divergent performance on Aug. 31. Cellid Co., Ltd. surged 27% amid renewed concerns over COVID-19, Onconic Therapeutics Inc. jumped 22% follow…
  • 2026-09-02 07:57:03
  • KIM SAE-MI
Technology

Cellid Co., Ltd. 'Smiles' Amid COVID-19 Resurgence… VUNO, Inc. 'Plummets' on Rights Offering Shock [Bio Spotlight]

On the 31st, stock prices in the biotech and healthcare sector showed mixed results depending on individual news. Cellid Co., Ltd.(299660)saw its stock price surge 27% amid concerns over a resurgence …
  • 2026-09-02 07:57:02
  • KIM SAE-MI
Technology

YuyuPharma’s ‘Bonki-ju’ Heads to Canada… Urgently Deployed to Address Local Supply Shortage

(Graphic: ChatGPT) As the supply shortage of calcitriol injections—used to treat patients with chronic kidney disease in Canada—persists, “Bonki-ju” from YuyuPharma(000220)is expected to be introdu…
  • 2026-09-01 11:02:02
  • Minji Son
Technology

Olix Pharmaceuticals, Inc. Splits Its Business by ‘Hierarchy’ Rather Than by Target… RNAi Technology Export Model Changes

Lee Dong-ki, CEO of Olix Pharmaceuticals, Inc. (Photo courtesy of Olix Pharmaceuticals, Inc.) “This is a new type of contract that is rare in the industry.”This is what an industry insider said re…
  • 2026-09-01 08:42:02
  • KIM SUNG-JIN
prev 31 32 33 34 35 36 37 38 39 40 next

PHARM EDAILY

Shorts

EDAILY
  • 92, Tongil-ro, Jung-gu, Seoul, Korea
  • +82 2 3772 0114
  • webmaster@edaily.co.kr

※ This article has been translated using AI technology for the convenience of readers.

EDAILY provides this translation on an “as is” basis and makes no warranties, express or implied, regarding its accuracy, reliability, completeness, merchantability, or fitness for a particular purpose.
Due to the limitations of machine translation, the translated content may differ from the original Korean article. In the event of any discrepancy, the original Korean version shall prevail.
EDAILY shall not be liable for any loss or damage arising from the use of, or reliance on, the translated content.

© 2026 Copyrights by edaily. All Rights Reserved.
Korea China Japan
English